

ARIPIPRAZOL INTRAMUSCULAR DEPOT

Bibliografía

1. Ficha Técnica de Abilify Maintena. Disponible en: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_Product_Information/human/002755/WC500156111.pdf
2. EPAR de Abilify Maintena. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/002755/WC500156105.pdf
3. W. Wolfgang Fleischhacker WW, Sanchez R, Perry PP, et al. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study*. The British Journal of Psychiatry 2014;205:135-44.
4. Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52 week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2012;73(5):617-24.
5. National Institute for Health and Clinical Excellence (NICE). Psychosis and schizophrenia in adults. Treatment and management. National Clinical Practice Guideline Number 178. 2014. <https://www.nice.org.uk/guidance/cg178>
6. Scottish Medicines Consortium. Aripiprazole 400 mg powder and solvent for prolonged release suspension for injection (Abilify Maintena®). SMC No. (962/14). http://www.scottishmedicines.org.uk/files/advice/aripiprazole_Abilify_FINAL_April_2014_for_website.pdf
7. NICE. ESNM39: Schizophrenia: aripiprazole prolonged-release suspension for injection. <http://www.nice.org.uk/advice/esnm39>
8. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatment meta-analysis. Lancet 2013; 382: 951-62.
9. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical antipsychotic trials of intervention effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 Sep 22; 353 (12): 1209-23.
10. Jones PB, Barnes TR, Davies L, et al. Controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Cost utility of the latest antipsychotic drugs in schizophrenia study (CUTLASS 1). Arch Gen Psychiatry 2006; 63: 1079-1087.
11. Laursen TM, Munk-Olsen T, Nordentoft M. Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 2007;68:899-907.
12. Kreyenbuhl J, Buchanan R, Dickerson FB, Dixon LB. The schizophrenia patient outcomes research team (PORT): updated treatment recommendations 2009. Schizophr Bull 2010;36:94-103.
13. Scottish Intercollegiate Guidelines Network (SIGN). Management of schizophrenia. Publication no. 131. 2013. Disponible en: <http://www.sign.ac.uk/guidelines/fulltext/131/index.html>
14. Kane JM, Kishimoto T, Correll CU. Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J Clin Epidemiol. 2013; 66 (8 Suppl):S37-41.
15. Kishimoto T1, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014; 40 (1): 192-213.
16. Olfson M1, Marcus SC, Ascher-Svanum H Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. Schizophr Bull. 2007;33(6):1379-87.
17. Informe de evaluación de aripiprazol. Comité Mixto de Evaluación de Medicamentos. Disponible en: http://www.osakidetza.euskadi.eus/contenidos/informacion/cevime_nuevo_medicamento/es_nme/adjuntos/Aripiprazol_informe_c.pdf